What the FDA labels say about taking them together
Fluvastatin and sofosbuvir/velpatasvir/voxilaprevir
Sofosbuvir/velpatasvir/voxilaprevir's FDA label of July 14, 2025 names fluvastatin in its drug interactions section; the fluvastatin labels PlainMeds reads (2) do not name sofosbuvir/velpatasvir/voxilaprevir. The sofosbuvir/velpatasvir/voxilaprevir label: “Coadministration with VOSEVI may increase the concentrations of atorvastatin, fluvastatin, lovastatin, and simvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. …”
Check it at the source: the fluvastatin FDA label on DailyMed (effective April 21, 2025, Teva Pharmaceuticals USA, Inc.); the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.).
What does the fluvastatin label say about sofosbuvir/velpatasvir/voxilaprevir?
Fluvastatin's label (effective April 21, 2025) and its 1 other brand-application label do not name sofosbuvir/velpatasvir/voxilaprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Fluvastatin), Teva Pharmaceuticals USA, Inc., effective April 21, 2025 (SPL set aad8b373-0aec-4efb-8e61-3d8114b31127), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir/voxilaprevir label say about fluvastatin?
Sofosbuvir/velpatasvir/voxilaprevir label, drug interactionsConcomitant Drug Class/Drug Name: atorvastatin fluvastatin lovastatin simvastatin; Effect on Concentration ↓ = decrease, ↑ = increase.: ↑ atorvastatin ↑ fluvastatin ↑ lovastatin ↑ simvastatin; Clinical Effect/Recommendation: Coadministration with VOSEVI may increase the concentrations of atorvastatin, fluvastatin, lovastatin, and simvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Use the lowest approved statin dose. If higher doses are needed, use the lowest necessary statin dose based on a risk/benefit assessment.
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fluvastatin | Sofosbuvir/velpatasvir/voxilaprevir | |
|---|---|---|
| Labeled for | High cholesterol | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.88 per tablet 80 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once